

Contents

1. Introduction	1
2. Critical review of psychoactive substances	1
2.1 Substances recommended for changes in scheduling	2
2.1.1 Dronabinol (INN)	2
2.1.2 Oripavine	4
2.2 Other substances critically reviewed	5
2.2.1 Buprenorphine (INN)	5
2.2.2 Butorphanol (INN)	8
2.2.3 Ketamine (INN)	9
2.2.4 Khat (<i>Catha edulis</i> Forsk.)	10
2.2.5 Zopiclone (INN)	12
3. Pre-review of psychoactive substances	13
3.1 Gamma-hydroxybutyric acid	13
3.2 Tramadol (INN)	14
4. Substances identified for future pre-review	15
4.1 Gamma-butyrolactone (GBL)	15
4.2 1,4-Butanediol	16
5. Guidelines for the WHO review of dependence-producing psychoactive substances for international control	16
5.1 Amending the current version of the guidelines	16
5.2 Interpretation of specific aspects of the guidelines	17
5.3 Access to information necessary for the evaluation of substances	18
6. Other matters	18
6.1 Activities of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)	18
6.2 Use of pharmacovigilance data for the assessment of dependence and abuse potential (procedures and methodology)	19
6.3 Promotion of education and information on the appropriate use of psychoactive drugs	19
6.4 Impact of international control on medical availability of substances	20
Acknowledgements	23
References	23